A new frontier in genetic engineering has galloped into the world of horse breeding. For the first time, researchers have used CRISPR–Cas9 gene-editing technology to modify the genome of horses, creating animals designed for superior athletic performance. The development, reported by The Nature, has sparked intense debate over ethics, tradition, and the future of animal breeding in Argentina’s popular polo community.
The five horses, clones of the renowned prize-winning steed Polo Pureza, were engineered to carry a modified version of the myostatin gene, which plays a key role in regulating muscle growth. This tweak is intended to enhance their speed. Scientists from the Buenos Aires-based non-profit research organization Kheiron Biotech used CRISPR in fetal fibroblast cells to create embryos that were then implanted into mares, resulting in the birth of the gene-edited foals approximately ten months ago.
While the innovation showcases the potential of genetic science, it has divided the polo world. Critics argue that such technologies threaten livelihoods and undermine the tradition of selective breeding, long considered both an art and a science in equestrian circles. In response to mounting concerns, the Argentine Polo Association has banned the use of gene-edited horses in the sport, following earlier prohibitions by organizations such as the International Federation for Equestrian Sports, which imposed a ban in 2019.
“This partnership between tradition and technology should be approached cautiously,” Molly McCue, a veterinary clinician scientist at the University of Minnesota, told The Nature. “It’s exciting that CRISPR works and can create altered horses, but we must balance innovation with animal welfare and cultural sensitivities.”
The debate around these CRISPR horses is part of a larger conversation about gene editing in animals, especially within agriculture. As The Nature reported, companies like Acceligen in the U.S. and other biotech firms are using CRISPR to create livestock with traits that address global challenges such as climate change, food security, and disease resistance.
For instance, Acceligen’s PRLR-SLICK cattle, which have edits in the prolactin receptor gene for heat tolerance, have been approved by the U.S. Food and Drug Administration (FDA) and could help farmers adapt to rising temperatures. Similarly, Genus, a UK-based company, has developed gene-edited pigs resistant to deadly swine diseases, while Revivicor’s GalSafe pigs offer hypoallergenic meat and potential organ transplant solutions for humans.
Yet, the expansion of CRISPR-edited animals has also raised serious ethical concerns. Long-term health effects, unintended mutations, and the potential spread of edits to wild populations remain areas requiring careful research and monitoring. “Are there unknown consequences with the changes they’re making that are going to appear over time?” McCue questioned in The Nature. The fact that edited traits are heritable further complicates the issue.
Biological ethicist Jeantine Lunshof from Harvard Medical School emphasized the need for informed public discourse. “It is natural for such discussions to arise,” she told The Nature. “The harms and benefits of particular uses should be weighed carefully, especially when it comes to animals and their welfare.”
As CRISPR technology continues to reshape animal breeding, the debate over its applications—whether for enhancing athletic ability in horses or improving resilience in livestock—will likely intensify. For Argentina’s polo community, the gene-edited horses represent both a scientific breakthrough and a cultural crossroads.
